News and Trends 11 Oct 2022 Gedea Biotech reports results from bacterial vaginosis trial Gedea Biotech has reported top-line results from a clinical study, NEFERTITI, of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). NEFERTITI is a placebo-controlled,… October 11, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 6 Sep 2021 Why We Desperately Need to Develop New Antifungals …tables, a small number of biotech companies are developing innovative new treatment options for these patients. Candida auris is a fungus that can infect humans, often those hospitalized and with… September 6, 2021 - 10 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2022 Poolbeg influenza trial successfully completed …close on schedule. No serious adverse events were reported. Poolbeg Pharma’s POLB 001 was found to be safe and well tolerated. Data analysis has commenced and full data read-out is… December 13, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Sep 2023 Five latest advancements in NASH research …seemed to be well-tolerated among the participants, with mild gastrointestinal issues being the most common side effect. But, no serious drug-related adverse events were reported. “We’re highly encouraged by the… September 15, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2023 Cancer Genomics: Technological innovation set to fuel research breakthroughs …splicing events, including 35 significantly associated with patient survival. Such technology edges us closer to the goal of diagnosing at the earliest possible stage and informing precision oncology treatment decisions…. February 1, 2023 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study …of each of the medicines. The most common adverse events in those treated with XTANDI plus leuprolide were fatigue, hot flush, and arthralgia and in those treated with XTANDI monotherapy… May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 27 Jun 2024 CRISPR-Cas13: how does the technology compare to its famous Cas9 cousin? …cleave ssRNA, is an extremely welcome proposition. RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutic modalities. Here are a few… June 27, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2022 TurtleTree produces first precision fermentation sustainable lactoferrin Singapore biotech company TurtleTree has announced production of LF+, the world’s first sustainable bovine lactoferrin created using precision fermentation technology. A key part of the company’s ongoing work with cultivated… August 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Sep 2022 Positive results from study of drug to treat patients with breast cancer published …Limited, a clinical stage biotech company has developed Pruxelutamide, an oral new generation AR antagonist which has shown promising activity in heavily pretreated AR+ mBC patients. The results were published… September 29, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 Prurigo nodularis treatment recommended for EU approval …results of the trial were generally consistent with the known safety profile of Dupixent in its approved dermatology indication. Adverse events more commonly observed with Dupixent compared to placebo included… November 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 26 Oct 2023 Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials …events,” including brain bleeding. Cassava Sciences accused of scientific misconduct in latest Alzheimer’s drug controversy Just this month, Cassava Sciences was the latest company to come under fire for its… October 26, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 9 Aug 2024 The therapeutic potential of circular RNA: Could it soon trump mRNA technology? …effective as single doses, and patients could suffer fewer adverse events since lower quantities of the active ingredient would be needed. Another way that circular RNA could be superior to… August 9, 2024 - 5 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email